Pathway Health Corp. announced a strategic partnership with Geocann that will bring VESIsorb® formulated products to the forefront of the rapidly evolving medical cannabis programs of leading Canadian pharmacies. Pathway, formerly The Clinic Network Canada Inc., owns and operates the largest chronic pain telehealth network in Canada, and has recently expanded its business model by finalizing agreements with some of the largest national retail pharmacy companies in Canada. Key elements of these agreements include a full-service collaboration, from pharmacist education programs to patient fulfillment of science-backed medical cannabis products.
“Geocann’s portfolio of medical cannabis products has set the benchmark for what pharmacists are demanding and health-conscious consumers expect,” Michael Steele, Chairman of Pathway said. “The unmatched supporting scientific evidence of VESIsorb® products has provided the needed platform to develop, co-brand, and distribute specialized cannabis products to our national footprint of leading pharmacies and pain clinics.”
“We are delighted to reach an agreement with Pathway that will provide access to our VESIsorb® formulated medical cannabis portfolio for millions of Canadians,” Jesse Lopez, CEO and founder of Geocann said. “Through its new business initiatives, Pathway is quickly becoming the leading referral site for pain products and services for thousands of pharmacies. Pathway’s expertise to reach the end-consumer through its strategic pharmacy partnerships will integrate seamlessly with the significant investments that Geocann has made in product safety, purity, and performance.”
Pathway and Geocann also have a keen focus on education initiatives that are aimed at reaching the approximately 42,000 licensed pharmacists working in more than 10,000 pharmacies. These include traditional Canadian Council on Continuing Education in Pharmacy (CCCEP) accredited bilingual programs and on-boarding tools such as the Medical Cannabis Management Program for Pharmacists.
“Preparing pharmacy professionals to play an active role in the medical cannabis market is a paramount priority for Pathway,” Steele said. “Health-conscious consumers depend on their pharmacies to provide clinically researched and proven products in addition to well-educated recommendations and guidance for the products they offer. Our partnership with Geocann gives us an unrivaled ability to offer these elements.”
Geocann has the exclusive global rights to the patented VESIsorb® drug delivery technology for cannabinoids, terpenes, and flavonoid formulations. The technology has been successfully applied to a wide range of medical cannabis product applications, including soft gel and hard-shell capsules, functional foods (e.g. gummies) and beverages, powder systems, tinctures, sublingual sprays, and topically applied formulations.
Geocann is a global cannabis organization led by experienced leadership with scientific and technical expertise for pioneering new innovations in natural health products and solutions. Its focus is combining clinically researched cannabinoids with technologically advanced and patented innovations that provide product differentiation with superior therapeutic performance and unmatched supporting evidence. Geocann owns a robust intellectual property portfolio, including the worldwide exclusivity for cannabinoids, terpenes, and flavonoids formulated with VESIsorb®. For more information, please visit www.geocann.com.
